论文部分内容阅读
目的:探讨肝癌患者经系统治疗后甲胎蛋白(AFP)变化对患者预后的影响。方法:对53例肝癌患者于入院后和系统治疗后分别于不同时间点测定血清AFP值后,将入院时AFP值作为基线,以变化50%作为标准分组,并进行无疾病进展生存时间(PFS)和总生存时间(OS)分析。结果:9例患者血清AFP值下降超过50%(A组),28例患者AFP值升高超过50%(B组),而AFP值变化小于50%(C组)的为16例。和C组相比,A组患者PFS明显延长(P<0.05),B组PFS明显缩短(P<0.05)。B组OS短于C组(P<0.01),而A组和C组间OS无明显差别(P>0.05)。结论:肝癌系统治疗前后的AFP值变化可作为临床上预后判断的标志之一。
Objective: To investigate the effect of AFP on the prognosis of patients with hepatocellular carcinoma after systemic therapy. Methods: AFP values of 53 HCC patients were measured at different time points after admission and after systemic treatment. The AFP values at admission were taken as the baseline, and the 50% change was taken as the standard group. The PFS ) And total survival (OS) analysis. Results: Serum AFP decreased by more than 50% in group A (group A), AFP increased by more than 50% in group B (group B), and group A changed in less than 50% (group C). Compared with group C, PFS in group A was significantly prolonged (P <0.05), and PFS in group B was significantly shorter (P <0.05). The OS of group B was shorter than that of group C (P <0.01), but there was no significant difference between group A and group C (P> 0.05). Conclusion: The change of AFP value before and after treatment of HCC can be used as one of the markers of clinical prognosis.